IMMUNITYBIO, INC. Convertible Notes Payable, Noncurrent
IMMUNITYBIO, INC. (IBRX) had Convertible Notes Payable, Noncurrent of $0 as of 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Long-Term Debt and Lease Obligation › Long-Term Debt, Excluding Current Maturities › Notes Payable, Noncurrent
us-gaap:ConvertibleLongTermNotesPayable · last filed 2025-03-03
- 2024-12-31: Convertible Notes Payable, Noncurrent $0.00.
- 2024-09-30: Convertible Notes Payable, Noncurrent $587.98M.
- 2024-06-30: Convertible Notes Payable, Noncurrent $584.11M.
- 2024-03-31: Convertible Notes Payable, Noncurrent $580.45M.
| Period end | Convertible Notes Payable, Noncurrent |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-03 |
| 2024-09-30 | $587.98M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $584.11M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $580.45M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $576.95M 10-K · filed 2025-03-03 |
| 2023-09-30 | $165.29M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $250.10M 10-Q · filed 2023-08-08 |
| 2022-12-31 | $241.27M 10-K · filed 2024-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |